<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">40687396</PMID><DateRevised><Year>2025</Year><Month>07</Month><Day>23</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2352-9067</ISSN><JournalIssue CitedMedium="Print"><Volume>59</Volume><PubDate><Year>2025</Year><Month>Aug</Month></PubDate></JournalIssue><Title>International journal of cardiology. Heart &amp; vasculature</Title><ISOAbbreviation>Int J Cardiol Heart Vasc</ISOAbbreviation></Journal><ArticleTitle>Impact of diabetes on three-year outcome after coronary stenting in patients with polyvascular atherosclerotic disease - a secondary analysis of the randomized TWENTE trials.</ArticleTitle><Pagination><StartPage>101741</StartPage><MedlinePgn>101741</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">101741</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ijcha.2025.101741</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="UNASSIGNED">The presence of polyvascular atherosclerotic disease is associated with a high-risk of adverse events following percutaneous coronary intervention (PCI). As the extent to which the presence of diabetes further increases this elevated risk is unclear, based on current literature, we sought to assess the long-term outcome after PCI in patients with polyvascular disease, comparing those with and without diabetes.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">The current study population consists of patients with known polyvascular disease, identified from a pooled patient-level database of 4 PCI trials in all-comers treated with new-generation drug-eluting stents; no exclusion criteria were set. The main composite endpoint was major adverse cardiac event (MACE: any myocardial infarction, emergent coronary bypass surgery, clinically indicated target lesion revascularization, or all-cause mortality).</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">695 patients had polyvascular disease of whom 208(29.9&#xa0;%) had diabetes. Patients with diabetes were older, had a higher body-mass-index, and had a higher prevalence of hypertension than those without diabetes. At 3-year follow-up, the incidence of MACE was significantly higher in polyvascular disease patients with diabetes (24.6&#xa0;% vs.16.4&#xa0;%, adj.HR:1.49, 95&#xa0;%CI:1.05-2.12, p&#xa0;=&#xa0;0.03), in particular insulin-treated patients, and was primarily attributable to a disparity in all-cause mortality which was more than twice as high in patients with diabetes (15.4&#xa0;% vs.7.2&#xa0;%, p&#xa0;&lt;&#xa0;0.001). Furthermore, the risk of repeated target vessel revascularization was higher in patients with diabetes (12.0&#xa0;% vs7.0&#xa0;%, adj.HR:1.88, 95&#xa0;%CI:1.12-3.16, p&#xa0;=&#xa0;0.02).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="UNASSIGNED">In the high-risk population of PCI patients with polyvascular disease, the presence of diabetes represents a profoundly significant additional risk factor at long-term follow-up, associated with significantly higher adverse event risks.<b>Trial registration:</b>ClinicalTrials.gov NCT01066650 NCT0133170 NCT01674803&#xa0;NCT02508714.</AbstractText><CopyrightInformation>&#xa9; 2025 The Authors.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>van Vliet</LastName><ForeName>Daphne</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Thoraxcentrum Twente, Medisch Spectrum Twente, Enschede, the Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Health Technology and Services Research, Faculty BMS, Technical Medical Centre, University of Twente, Enschede, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pinxterhuis</LastName><ForeName>Tineke H</ForeName><Initials>TH</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Thoraxcentrum Twente, Medisch Spectrum Twente, Enschede, the Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Health Technology and Services Research, Faculty BMS, Technical Medical Centre, University of Twente, Enschede, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ploumen</LastName><ForeName>Eline H</ForeName><Initials>EH</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Thoraxcentrum Twente, Medisch Spectrum Twente, Enschede, the Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Health Technology and Services Research, Faculty BMS, Technical Medical Centre, University of Twente, Enschede, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kok</LastName><ForeName>Marlies M</ForeName><Initials>MM</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Thoraxcentrum Twente, Medisch Spectrum Twente, Enschede, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Buiten</LastName><ForeName>Rosaly A</ForeName><Initials>RA</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Thoraxcentrum Twente, Medisch Spectrum Twente, Enschede, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zocca</LastName><ForeName>Paolo</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Thoraxcentrum Twente, Medisch Spectrum Twente, Enschede, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Roguin</LastName><ForeName>Ariel</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Hillel Yaffe Medical Center, Hadera and B. Rappaport-Faculty of Medicine, Israel, Institute of Technology, Haifa, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schotborgh</LastName><ForeName>Carl E</ForeName><Initials>CE</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Haga Hospital, The Hague, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Anthonio</LastName><ForeName>Rutger L</ForeName><Initials>RL</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Treant Zorggroep, Scheper Hospital, Emmen, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Danse</LastName><ForeName>Peter W</ForeName><Initials>PW</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Rijnstate Hospital, Arnhem, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Benit</LastName><ForeName>Edouard</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Jessa Hospital, Hasselt, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aminian</LastName><ForeName>Adel</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Centre Hospitalier Universitaire de Charleroi, Charleroi, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Cardiology, Ziekenhuisgroep Twente, Almelo and Hengelo, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Doggen</LastName><ForeName>Carine J M</ForeName><Initials>CJM</Initials><AffiliationInfo><Affiliation>Department of Health Technology and Services Research, Faculty BMS, Technical Medical Centre, University of Twente, Enschede, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>von Birgelen</LastName><ForeName>Clemens</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Thoraxcentrum Twente, Medisch Spectrum Twente, Enschede, the Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Health Technology and Services Research, Faculty BMS, Technical Medical Centre, University of Twente, Enschede, the Netherlands.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT01066650</AccessionNumber><AccessionNumber>NCT02508714</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>07</Month><Day>06</Day></ArticleDate></Article><MedlineJournalInfo><Country>Ireland</Country><MedlineTA>Int J Cardiol Heart Vasc</MedlineTA><NlmUniqueID>101649525</NlmUniqueID><ISSNLinking>2352-9067</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Coronary artery disease</Keyword><Keyword MajorTopicYN="N">Diabetes mellitus</Keyword><Keyword MajorTopicYN="N">Percutaneous coronary intervention</Keyword><Keyword MajorTopicYN="N">Peripheral arterial disease</Keyword><Keyword MajorTopicYN="N">Polyvascular disease</Keyword></KeywordList><CoiStatement>The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>2</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>6</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>6</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>7</Month><Day>21</Day><Hour>12</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>7</Month><Day>21</Day><Hour>12</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>7</Month><Day>21</Day><Hour>7</Hour><Minute>15</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>7</Month><Day>6</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40687396</ArticleId><ArticleId IdType="pmc">PMC12272603</ArticleId><ArticleId IdType="doi">10.1016/j.ijcha.2025.101741</ArticleId><ArticleId IdType="pii">S2352-9067(25)00144-7</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Vidakovic R., Schouten O., Kuiper R., et al. The prevalence of polyvascular disease in patients referred for peripheral arterial disease. Eur J Vasc Endovasc Surg. 2009;38:435&#x2013;440. doi: 10.1016/j.ejvs.2009.05.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejvs.2009.05.006</ArticleId><ArticleId IdType="pubmed">19560948</ArticleId></ArticleIdList></Reference><Reference><Citation>Morikami Y., Natsuaki M., Morimoto T., et al. Impact of polyvascular disease on clinical outcomes in patients undergoing coronary revascularization: an observation from the CREDO-Kyoto Registry Cohort-2. Atherosclerosis. 2013;2(228):426&#x2013;431. doi: 10.1016/j.atherosclerosis.2013.04.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.atherosclerosis.2013.04.005</ArticleId><ArticleId IdType="pubmed">23623262</ArticleId></ArticleIdList></Reference><Reference><Citation>Gutierrez J.A., Aday A.W., Patel M.R., Jones W.S. Polyvascular disease: reappraisal of the current clinical landscape. Circ Cardiovasc Interv. 2019;12(12)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7660526</ArticleId><ArticleId IdType="pubmed">31833412</ArticleId></ArticleIdList></Reference><Reference><Citation>Su&#xe1;rez C., Zeymer U., Limbourg T., et al. REACH Registry investigators. Influence of polyvascular disease on cardiovascular event rates. Insights from the REACH Registry. Vasc Med. 2010;15(4):259&#x2013;265. doi: 10.1177/1358863X10373299.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1358863X10373299</ArticleId><ArticleId IdType="pubmed">20724374</ArticleId></ArticleIdList></Reference><Reference><Citation>Kobo O., Saada M., von Birgelen C., et al. Impact of multisite artery disease on clinical outcomes after percutaneous coronary intervention: an analysis from the e-Ultimaster registry. Eur Heart J Qual Care Clin Outcomes. 2023 Jun 21;9(4):417&#x2013;426.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10284265</ArticleId><ArticleId IdType="pubmed">35876646</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramzy J., Andrianopoulos N., Roberts L., et al. Melbourne Interventional Group (MIG). Outcomes in patients with peripheral vascular disease following percutaneous coronary intervention. Catheter. Cardiovasc. Interv. 2019 Oct 1;94(4):588&#x2013;597. doi: 10.1002/ccd.28145.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ccd.28145</ArticleId><ArticleId IdType="pubmed">30790432</ArticleId></ArticleIdList></Reference><Reference><Citation>Nikolsky E., Mehran R., Mintz G.S., et al. Impact of symptomatic peripheral arterial disease on 1-year mortality in patients undergoing percutaneous coronary interventions. J. Endovasc. Ther. 2004 Feb;11(1):60&#x2013;70. doi: 10.1177/152660280401100108.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/152660280401100108</ArticleId><ArticleId IdType="pubmed">14748627</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Der Meer M.G., Cramer M.J., Van Der Graaf Y., Appelman Y., Doevendans P.A., Nathoe H.M. The impact of polyvascular disease on long-term outcome in percutaneous coronary intervention patients. Eur. J. Clin. Invest. 2014;44:231&#x2013;239.</Citation><ArticleIdList><ArticleId IdType="pubmed">24372467</ArticleId></ArticleIdList></Reference><Reference><Citation>Pinxterhuis T.H., Ploumen E.H., van Vliet D., et al. Ten-year mortality after treating obstructive coronary atherosclerosis with contemporary stents in patients with or without concomitant peripheral arterial disease. Atherosclerosis. 2024 May;392 doi: 10.1016/j.atherosclerosis.2024.117488.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.atherosclerosis.2024.117488</ArticleId><ArticleId IdType="pubmed">38598970</ArticleId></ArticleIdList></Reference><Reference><Citation>Ploumen E.H., Pinxterhuis T.H., Zocca P., et al. Impact of prediabetes and diabetes on 3-year outcome of patients treated with new-generation drug-eluting stents in two large-scale randomized clinical trials. Cardiovasc. Diabetol. 2021 Oct 30;20(1):217. doi: 10.1186/s12933-021-01405-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12933-021-01405-4</ArticleId><ArticleId IdType="pmc">PMC8557556</ArticleId><ArticleId IdType="pubmed">34717627</ArticleId></ArticleIdList></Reference><Reference><Citation>Konigstein M., Ben-Yehuda O., Smits P.C., et al. Outcomes among Diabetic patients Undergoing Percutaneous Coronary intervention with Contemporary Drug-Eluting Stents: Analysis from the BIONICS Randomized Trial. JACC Cardiovasc. Interv. 2018 Dec 24;11(24):2467&#x2013;2476. doi: 10.1016/j.jcin.2018.09.033.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcin.2018.09.033</ArticleId><ArticleId IdType="pubmed">30573057</ArticleId></ArticleIdList></Reference><Reference><Citation>Koskinas K.C., Siontis G.C., Piccolo R., et al. Impact of Diabetic Status on Outcomes after Revascularization with Drug-Eluting Stents in Relation to Coronary Artery Disease Complexity: Patient-Level Pooled Analysis of 6081 patients. Circ. Cardiovasc. Interv. 2016 Feb;9(2) doi: 10.1161/CIRCINTERVENTIONS.115.003255.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCINTERVENTIONS.115.003255</ArticleId><ArticleId IdType="pubmed">26823484</ArticleId></ArticleIdList></Reference><Reference><Citation>Verma S., Bhatt D.L., Bain S.C., Buse J.B., Mann J.F.E., Marso S.P., Nauck M.A., Poulter N.R., Pratley R.E., Zinman B., Michelsen M.M., Monk Fries T., Rasmussen S., Leiter L.A. LEADER Publication Committee on behalf of the LEADER Trial investigators. effect of Liraglutide on Cardiovascular events in patients with Type 2 Diabetes Mellitus and Polyvascular Disease: results of the LEADER Trial. Circulation. 2018 May 15;137(20):2179&#x2013;2183. doi: 10.1161/CIRCULATIONAHA.118.033898.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.118.033898</ArticleId><ArticleId IdType="pubmed">29760228</ArticleId></ArticleIdList></Reference><Reference><Citation>Gutierrez J.A., Scirica B.M., Bonaca M.P., Steg P.G., Mosenzon O., Hirshberg B., Im K., Raz I., Braunwald E., Bhatt D.L. Prevalence and Outcomes of Polyvascular (Coronary, Peripheral, or Cerebrovascular) disease in patients with Diabetes Mellitus (from the SAVOR-TIMI 53 Trial) Am. J. Cardiol. 2019 Jan 1;123(1):145&#x2013;152. doi: 10.1016/j.amjcard.2018.09.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.amjcard.2018.09.014</ArticleId><ArticleId IdType="pubmed">30366601</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonaca M.P., Gutierrez J.A., Cannon C., et al. Polyvascular disease, type 2 diabetes, and long-term vascular risk: a secondary analysis of the IMPROVE-IT trial. Lancet Diabetes Endocrinol. 2018 Dec;6(12):934&#x2013;943. doi: 10.1016/S2213-8587(18)30290-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-8587(18)30290-0</ArticleId><ArticleId IdType="pubmed">30396865</ArticleId></ArticleIdList></Reference><Reference><Citation>von Birgelen C., Basalus M.W., Tandjung K., et al. A randomized controlled trial in second-generation zotarolimus-eluting Resolute stents versus everolimus-eluting Xience V stents in real-world patients: the TWENTE trial. J. Am. Coll. Cardiol. 2012;59(15):1350&#x2013;1361. doi: 10.1016/j.jacc.2012.01.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacc.2012.01.008</ArticleId><ArticleId IdType="pubmed">22341737</ArticleId></ArticleIdList></Reference><Reference><Citation>von Birgelen C., Sen H., Lam M.K., et al. Third-generation zotarolimus-eluting and everolimus-eluting stents in all-comer patients requiring a percutaneous coronary intervention (DUTCH PEERS): a randomised, single-blind, multicentre, non-inferiority trial. Lancet. 2014;383(9915):413&#x2013;423. doi: 10.1016/S0140-6736(13)62037-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(13)62037-1</ArticleId><ArticleId IdType="pubmed">24183564</ArticleId></ArticleIdList></Reference><Reference><Citation>von Birgelen C., Kok M.M., van der Heijden L.C., et al. Very thin strut biodegradable polymer everolimus-eluting and sirolimus-eluting stents versus durable polymer zotarolimus-eluting stents in allcomers with coronary artery disease (BIO-RESORT): a three-arm, randomised, non-inferiority trial. Lancet. 2016;388(10060):2607&#x2013;2617. doi: 10.1016/S0140-6736(16)31920-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(16)31920-1</ArticleId><ArticleId IdType="pubmed">27806902</ArticleId></ArticleIdList></Reference><Reference><Citation>von Birgelen C., Zocca P., Buiten R.A., Jessurun G.A.J., et al. Thin composite wire strut, durable polymer-coated (Resolute Onyx) versus ultrathin cobalt-chromium strut, bioresorbable polymer-coated (Orsiro) drug-eluting stents in allcomers with coronary artery disease (BIONYX): an international, single-blind, randomised non-inferiority trial. Lancet. 2018;392(10154):1235&#x2013;1245. doi: 10.1016/S0140-6736(18)32001-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(18)32001-4</ArticleId><ArticleId IdType="pubmed">30253879</ArticleId></ArticleIdList></Reference><Reference><Citation>Pinxterhuis T.H., Ploumen E.H., Zocca P., et al. Outcome after percutaneous coronary intervention with contemporary stents in patients with concomitant peripheral arterial disease: a patient-level pooled analysis of four randomized trials. Atherosclerosis. 2022 Aug;355:52&#x2013;59. doi: 10.1016/j.atherosclerosis.2022.05.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.atherosclerosis.2022.05.002</ArticleId><ArticleId IdType="pubmed">35641327</ArticleId></ArticleIdList></Reference><Reference><Citation>Pinxterhuis T.H., Ploumen E.H., Zocca P., et al. Outcome of percutaneous coronary intervention using ultrathin-strut biodegradable polymer sirolimus-eluting versus thin-strut durable polymer zotarolimus-eluting stents in patients with comorbid peripheral arterial disease: a post-hoc analysis from two randomized trials. Cardiovasc Diagn Ther. 2023 Aug 31;13(4):673&#x2013;685. doi: 10.21037/cdt-22-584.</Citation><ArticleIdList><ArticleId IdType="doi">10.21037/cdt-22-584</ArticleId><ArticleId IdType="pmc">PMC10478025</ArticleId><ArticleId IdType="pubmed">37675090</ArticleId></ArticleIdList></Reference><Reference><Citation>Cutlip D.E., Windecker S., Mehran R., et al. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation. 2007;115(17):2344&#x2013;2351. doi: 10.1161/CIRCULATIONAHA.106.685313.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.106.685313</ArticleId><ArticleId IdType="pubmed">17470709</ArticleId></ArticleIdList></Reference><Reference><Citation>Vranckx P., Cutlip D.E., Mehran R., et al. Myocardial infarction adjudication in contemporary all-comer stent trials: balancing sensitivity and specificity. Addendum to the historical MI definitions used in stent studies. EuroIntervention. 2010;5(7):871&#x2013;874. doi: 10.4244/eijv5i7a146.</Citation><ArticleIdList><ArticleId IdType="doi">10.4244/eijv5i7a146</ArticleId><ArticleId IdType="pubmed">20142206</ArticleId></ArticleIdList></Reference><Reference><Citation>Kobo O., Contractor T., Mohamed M.O., et al. Impact of pre-existent vascular and poly-vascular disease on acute myocardial infarction management and outcomes: an analysis of 2 million patients from the National Inpatient Sample. Int. J. Cardiol. 2021 Mar;15(327):1&#x2013;8. doi: 10.1016/j.ijcard.2020.11.051.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijcard.2020.11.051</ArticleId><ArticleId IdType="pubmed">33271206</ArticleId></ArticleIdList></Reference><Reference><Citation>Samsky M.D., Mentz R.J., Stebbins A., et al. Polyvascular disease and increased risk of cardiovascular events in patients with type 2 diabetes: Insights from the EXSCEL trial. Atherosclerosis. 2021 Dec;338:1&#x2013;6. doi: 10.1016/j.atherosclerosis.2021.10.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.atherosclerosis.2021.10.011</ArticleId><ArticleId IdType="pmc">PMC8702379</ArticleId><ArticleId IdType="pubmed">34741929</ArticleId></ArticleIdList></Reference><Reference><Citation>Ormazabal V., Nair S., Elfeky O., Aguayo C., Salomon C., Zu&#xf1;iga F.A. Association between insulin resistance and the development of cardiovascular disease. Cardiovasc. Diabetol. 2018 Aug 31;17(1):122. doi: 10.1186/s12933-018-0762-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12933-018-0762-4</ArticleId><ArticleId IdType="pmc">PMC6119242</ArticleId><ArticleId IdType="pubmed">30170598</ArticleId></ArticleIdList></Reference><Reference><Citation>Gatuz M.V., Abu-Fanne R., Abramov D., Mamas M.A., Roguin A., Kobo O. Diabetes and its Impact on Cardiogenic shock Outcomes in Acute Myocardial Infarction with Polyvascular Disease: a Comparative Analysis. Biomedicines. 2024 Aug 20;12(8):1900. doi: 10.3390/biomedicines12081900.\.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biomedicines12081900.\</ArticleId><ArticleId IdType="pmc">PMC11351229</ArticleId><ArticleId IdType="pubmed">39200364</ArticleId></ArticleIdList></Reference><Reference><Citation>American Diabetes Association Professional Practice Committee. 5. Facilitating Positive Health Behaviors and Well-being to Improve Health Outcomes: Standards of Care in Diabetes-2025. Diabetes Care. 2025 Jan 1;48(1 Suppl 1):S86-S127. doi: 10.2337/dc25-S005.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11635047</ArticleId><ArticleId IdType="pubmed">39651983</ArticleId></ArticleIdList></Reference><Reference><Citation>Mazzolai L, Teixido-Tura G, Lanzi S, et al; ESC Scientific Document Group. 2024 ESC Guidelines for the management of peripheral arterial and aortic diseases. Eur Heart J. 2024 Aug 30:ehae179. doi: 10.1093/eurheartj/ehae179.</Citation><ArticleIdList><ArticleId IdType="pubmed">39210722</ArticleId></ArticleIdList></Reference><Reference><Citation>Verma S., Mazer C.D., Al-Omran M., et al. Cardiovascular Outcomes and Safety of Empagliflozin in patients with Type 2 Diabetes Mellitus and Peripheral Artery Disease: a Subanalysis of EMPA-REG OUTCOME. Circulation. 2018;137(4):405&#x2013;407. doi: 10.1161/CIRCULATIONAHA.117.032031.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.117.032031</ArticleId><ArticleId IdType="pubmed">29133602</ArticleId></ArticleIdList></Reference><Reference><Citation>Verma S, Al-Omran M, Leiter LA, et al. Cardiovascular efficacy of liraglutide and semaglutide in individuals with diabetes and peripheral artery disease. Diabetes Obes Metab. 2022 Jul;24(7):1288-1299. doi: 10.1111.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9325529</ArticleId><ArticleId IdType="pubmed">35332654</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>